The activation and regulation of IL-17 receptor mediated signaling

Cytokine

Volumn 62, Issue 2, 2013, Pages 175-182

  Song, Xinyang ^a   Qian, Youcun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Act1; Inflammation; Interleukin 17; Signal transduction

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17C; INTERLEUKIN 17F; INTERLEUKIN 25; PROTEIN ACT1; REGULATOR PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; CCAAT ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TRAF3IP2 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; IMMUNOLOGY; METABOLISM; MOUSE; TH17 CELL;

ANIMALS; AUTOIMMUNE DISEASES; CCAAT-ENHANCER-BINDING PROTEINS; HUMANS; INTERLEUKIN-17; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION; TH17 CELLS; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876812894     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.03.014     Document Type: Review

References (98)

1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454(7203):428-435.
2. Kuchroo V.K., et al. Dysregulation of immune homeostasis in autoimmune diseases. Nat Med 2012, 18(1):42-47.
3. Cho J.H., Gregersen P.K. Genomics and the multifactorial nature of human autoimmune disease. New Engl J Med 2011, 365(17):1612-1623.
4. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011, 121(6):2111-2117.
5. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 2012, 30:677-706.
6. Iwakura Y., et al. Functional specialization of interleukin-17 family members. Immunity 2011, 34(2):149-162.
7. Korn T., et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
8. Cua D.J., Tato C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010, 10(7):479-489.
9. Zhu S., Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012, 122(11):487-511.
10. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9(8):556-567.
11. Ron D., Fuchs Y., Chorev D.S. Know thy Sef: a novel class of feedback antagonists of receptor tyrosine kinase signaling. Int J Biochem Cell Biol 2008, 40(10):2040-2052.
12. Mellett M., et al. Orphan receptor IL-17RD tunes IL-17A signalling and is required for neutrophilia. Nat Commun 2012, 3:1119.
13. Ely L.K., Fischer S., Garcia K.C. Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 2009, 10(12):1245-1251.
14. Zhu S., et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat Med 2012, 18(7):1077-1086.
15. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. New Engl J Med 2009, 361(9):888-898.
16. Nakae S., et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171(11):6173-6177.
17. Yang X.O., et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008, 205(5):1063-1075.
18. Hu Y., et al. IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 2010, 184(8):4307-4316.
19. Wong C.K., et al. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000, 9(8):589-593.
20. Wong C.K., et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008, 127(3):385-393.
21. Rizzo H.L., et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 2010, 186(3):1495-1502.
22. Ito R., et al. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun 2008, 377(1):12-16.
23. Emamaullee J.A., et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009, 58(6):1302-1311.
24. Ishigame H., et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009, 30(1):108-119.
25. Nakae S., et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002, 17(3):375-387.
26. Wang L., et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206(7):1457-1464.
27. Chae W.J., et al. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA 2010, 107(12):5540-5544.
28. Wu S., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009, 15(9):1016-1022.
29. Kryczek I., et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114(2):357-359.
30. Aujla S.J., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008, 14(3):275-281.
31. Lin Y., et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009, 31(5):799-810.
32. Saijo S., et al. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 2010, 32(5):681-691.
33. Toy D., et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006, 177(1):36-39.
34. Hurst S.D., et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol 2002, 169(1):443-453.
35. Kim M.R., et al. Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood 2002, 100(7):2330-2340.
36. Pan G., et al. Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol 2001, 167(11):6559-6567.
37. Tamachi T., et al. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J Allergy Clin Immunol 2006, 118(3):606-614.
38. Fallon P.G., et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med 2006, 203(4):1105-1116.
39. Owyang A.M., et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med 2006, 203(4):843-849.
40. Zhao A., et al. Critical role of IL-25 in nematode infection-induced alterations in intestinal function. J Immunol 2010, 185(11):6921-6929.
41. Ballantyne S.J., et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2007, 120(6):1324-1331.
42. Angkasekwinai P., et al. Regulation of IL-9 expression by IL-25 signaling. Nat Immunol 2010, 11(3):250-256.
43. Rickel E.A., et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 2008, 181(6):4299-4310.
44. Claudio E., et al. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J Immunol 2009, 182(3):1617-1630.
45. Swaidani S., et al. The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation. J Immunol 2009, 182(3):1631-1640.
46. Kang Z., et al. Epithelial Cell-specific act1 adaptor mediates interleukin-25-dependent helminth expulsion through expansion of Lin(-)c-Kit(+) Innate Cell Population. Immunity 2012, 36(5):821-833.
47. Qian Y., et al. IL-17 signaling in host defense and inflammatory diseases. Cell Mol Immunol 2010, 7(5):328-333.
48. Song X., et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol 2011, 12(12):1151-1158.
49. Ramirez-Carrozzi V., et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 2011, 12(12):1159-1166.
50. Chang S.H., et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 2011, 35(4):611-621.
51. Rouvier E., et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993, 150(12):5445-5456.
52. Hartupee J., et al. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007, 179(6):4135-4141.
53. Huang F., et al. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J Immunol 2007, 179(10):6504-6513.
54. Saleh A., et al. Critical role for STAT3 in IL-17A-mediated CCL11 expression in human airway smooth muscle cells. J Immunol 2009, 182(6):3357-3365.
55. Ho A.W., Gaffen S.L. IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol 2009, 32(1):33-42.
56. Chung J.Y., et al. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002, 115(Pt 4):679-688.
57. Schwandner R., Yamaguchi K., Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med 2000, 191(7):1233-1240.
58. Hartupee J., et al. IL-17 signaling for mRNA stabilization does not require TNF receptor-associated factor 6. J Immunol 2009, 182(3):1660-1666.
59. Novatchkova M., et al. The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem Sci 2003, 28(5):226-229.
60. Chang S.H., Park H., Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006, 281(47):35603-35607.
61. Qian Y., et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007, 8(3):247-256.
62. Chen Z.J. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005, 7(8):758-765.
63. Liu C et al. A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation. Sci Signal 2011;4(197):ra72.
64. Maitra A., et al. Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. Proc Natl Acad Sci USA 2007, 104(18):7506-7511.
65. Onishi R.M., et al. SEF/IL-17R (SEFIR) is not enough: an extended SEFIR domain is required for il-17RA-mediated signal transduction. J Biol Chem 2010, 285(43):32751-32759.
66. Sonder S.U., et al. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J Biol Chem 2011, 286(15):12881-12890.
67. Ho A.W., et al. IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J Immunol 2010, 185(2):1063-1070.
68. Sun D., et al. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol 2011, 12(9):853-860.
69. Bulek K., et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 2011, 12(9):844-852.
70. Wang C., et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol 2012, 14(1):72-81.
71. Strange A., et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010, 42(11):985-990.
72. Ellinghaus E., et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010, 42(11):991-995.
73. Huffmeier U., et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010, 42(11):996-999.
74. Shen F., et al. IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Sci Signal 2009, 2(59):ra8.
75. Hacker H., et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006, 439(7073):204-207.
76. Oganesyan G., et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 2006, 439(7073):208-211.
77. Tseng P.H., et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol 2009, 11(1):70-75.
78. Cheng G., et al. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995, 267(5203):1494-1498.
79. Krajewski S., et al. Immunohistochemical analysis of in vivo patterns of TRAF-3 expression, a member of the TNF receptor-associated factor family. J Immunol 1997, 159(12):5841-5852.
80. He J.Q., et al. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J Exp Med 2006, 203(11):2413-2418.
81. Xie P., et al. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007, 27(2):253-267.
82. Gardam S., et al. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008, 28(3):391-401.
83. Zhu S., et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J Exp Med 2010, 207(12):2647-2662.
84. Zepp J.A., et al. Cutting edge: TNF receptor-associated factor 4 restricts IL-17-mediated pathology and signaling processes. J Immunol 2012, 189(1):33-37.
85. Nakayama K.I., Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006, 6(5):369-381.
86. Shi P et al. Persistent stimulation with interleukin-17 desensitizes cells through SCFbeta-TrCP-mediated degradation of Act1. Sci Signal 2011;4(197):ra73.
87. Qu F., et al. TRAF6-dependent Act1 phosphorylation by the I-kappaB kinase-related kinases suppresses interleukin-17-induced NF-kappaB activation. Mol Cell Biol 2012, 32(19):3925-3937.
88. Zhong B., et al. Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25. Nat Immunol 2012, 13(11):1110-1117.
89. Qian Y., et al. Act1, a negative regulator in CD40- and BAFF-mediated B cell survival. Immunity 2004, 21(4):575-587.
90. Giltiay N.V., et al. The adaptor molecule Act1 regulates BAFF responsiveness and self-reactive B cell selection during transitional B cell maturation. J Immunol 2010, 185(1):99-109.
91. Qian Y., et al. Role of NF kappa B activator Act1 in CD40-mediated signaling in epithelial cells. Proc Natl Acad Sci USA 2002, 99(14):9386-9391.
92. Qian Y., et al. Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren's syndrome. Eur J Immunol 2008, 38(8):2219-2228.
93. Pisitkun P., et al. The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody. Arthritis Rheum 2010, 62(11):3334-3344.
94. Kang Z., et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010, 32(3):414-425.
95. Kang Z., et al. IL-17-induced Act1-mediated signaling is critical for cuprizone-induced demyelination. J Neurosci 2012, 32(24):8284-8292.
96. Pisitkun P., et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012, 37(6):1104-1115.
97. Ciccacci C., et al. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2012, 7(1):44-52.
98. Swaidani S., et al. T cell-derived Act1 is necessary for IL-25-mediated Th2 responses and allergic airway inflammation. J Immunol 2011, 187(6):3155-3164.